U.S. Markets close in 48 mins.

Alexion Pharmaceuticals, Inc. (ALXN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
133.26+2.19 (+1.67%)
As of 3:12PM EDT. Market open.
People also watch
REGNBMRNVRTXBIIBCELG
Full screen
Previous Close131.07
Open139.00
Bid133.60 x 200
Ask133.75 x 100
Day's Range132.24 - 142.47
52 Week Range96.18 - 145.42
Volume3,955,762
Avg. Volume3,149,757
Market Cap29.92B
Beta1.26
PE Ratio (TTM)63.49
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com3 hours ago

    Alexion: Thank You For Your Patience?

    Shares of Alexion Pharmaceuticals (ALXN) are rising today after the biotech company beat earnings forecasts and raised its guidance. Leerink analyst Geoffrey Porges and Bradley Canino call today's report "the most important" of the large-cap biotech stocks: This morning Alexion announced Q2 revenue of $912mm, which was a 7% beat against consensus of $849mm and an 8% beat vs. our estimate of $846mm (which implied sequentially lower revenue given management’s conservative commentary last quarter and the attrition of patients on Soliris to clinical trials). Shares of Alexion Pharmaceuticals have gained 2% to $133.72 at 12:18 p.m. today, but had been up as much as 8.6% earlier today.

  • Associated Press3 hours ago

    Alexion tops Street 2Q forecasts

    On a per-share basis, the New Haven, Connecticut-based company said it had profit of 73 cents. Earnings, adjusted for one-time gains and costs, were $1.56 per share. The results beat Wall Street expectations. ...

  • American City Business Journals4 hours ago

    ​Alexion cuts ties with two Cambridge biotechs in reorganization

    Alexion Pharmaceuticals said Thursday that it’s scrapping a handful of drug development programs as part of a reorganization, including its partnership deals with a pair of Cambridge biotechs. Moderna : Alexion’s 2014 deal with Moderna, one of the state’s largest privately-held biotechs, covered treatments that use messenger RNA, or mRNA — molecules that recruit the body's own cells to create proteins to fight rare diseases. Under that agreement, Alexion paid Moderna $100 million upfront in exchange for the option to partner on up to 10 products.